Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, November 4, 2022
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
[ Fri, Nov 04th 2022
] - WOPRAI
Matthew Sykes Maintained (CDNA) at Strong Buy with Decreased Target to $40 on, Nov 4th, 2022
Matthew Sykes of Goldman Sachs, Maintained "CareDx, Inc" (CDNA) at Strong Buy with Decreased Target from $45 to $40 on, Nov 4th, 2022.
Matthew has made no other calls on CDNA in the last 4 months.
There is 1 other peer that has a rating on CDNA. Out of the 1 peers that are also analyzing CDNA, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Andrew Cooper of "Raymond James" Maintained at Strong Buy with Decreased Target to $35 on, Wednesday, August 10th, 2022
